Musculoskeletal Adverse Events Following BCMA CAR-T Cell Therapy in Multiple Myeloma: Clinical Characteristics and Immune Correlates
{{output}}
Background: Chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA) has revolutionized treatment for relapsed/refractory multiple myeloma (RRMM). While life-threatening toxicities like cytokine... ...
